Mepivacaine HCL
PreclinicalSmall molecule
Mepivacaine HCL is one of 31 small molecule programs targeting Pulpitis. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Pulpitis
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Decadron
QQuince Therapeutics S.p.A.
Approved
Tylenol
KKenvue Brands
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Marcaine
IInnocoll
Approved
Medrol
PfizerPhase 3
Advil
KKenvue Brands
Phase 3
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy1 trial
Anesthetic Efficacy Of 4% ArtpharmaDent Versus 2% Mepecaine-L in Extraction of Lower First Primary Molars
Unknown status·—·N/A·NCT03942991·20 enrolled
Infiltration1 trial
The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies
Unknown status·—·Phase 4·NCT03264586·200 enrolled
Pulpitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mepivacaine HCL. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCairo University